黴漿菌檢測市場 - 全球產業規模、佔有率、趨勢、機會及預測（按產品、技術、應用、最終用戶、地區和競爭格局分類），2021-2031年

全球黴漿菌檢測市場預計將從 2025 年的 10.9792 億美元成長到 2031 年的 23.4842 億美元，複合年成長率為 13.51%。

黴漿菌檢測涉及一系列分析通訊協定，旨在識別細胞庫、原料和成品生物製藥產品中的支原體污染，以確保病患安全。該市場的主要驅動力是生物製藥產量的成長以及嚴格的監管要求，這些要求規定產品在上市前必須不含外來性物質。此外，需要嚴格品質保證的先進治療藥物的商業性化也成為重要的成長引擎。根據再生醫學聯盟發布的2025年報告，全球細胞和基因療法收入的35%將來自美國以外地區，凸顯了生物製藥產業的國際化程度，而這需要強大的檢測能力。

儘管市場需求強勁，但由於檢驗旨在取代傳統28天培養法的快速替代方法面臨監管方面的困難，成長受到阻礙。製造商在證明更快速、自動化的技術能夠達到與既定藥典標準相當的檢測極限方面，常常面臨重大挑戰。這些檢驗難題往往會延緩高效檢測方案在保存期限短的治療藥物中的應用。

市場促進因素

全球對生物製藥和生物相似藥日益成長的需求是黴漿菌檢測市場的主要驅動力，從根本上改變了品管標準。隨著製藥開發商競相將複雜的分子商業化，為保障患者健康，強制性批次放行檢測中對外來性的病原體進行檢測的需求也相應成長。監管機構的持續行動也支持了這一趨勢。例如，Fierce Pharma在2026年1月通報稱，美國FDA藥物評估與研究中心在2025年核准了46種新藥。這些新治療方法的不斷湧現需要嚴格的無菌檢驗和擴展的檢測通訊協定，以最大限度地降低產品生命週期內的污染風險。

同時，生物製藥生產能力的顯著擴張正在推動市場成長，各公司紛紛升級基礎設施以滿足全球供應需求。新的生產基地需要進行全面的驗證，包括公用設施監測和原料分析，這導致黴漿菌檢測方法的使用量顯著增加。例如，安進公司在2025年9月的新聞稿中宣布，將投資6.5億美元擴大在美國的生產網路，並建立需要生物安全監測的新營運基地。此外，這種擴張也體現在契約製造業。三星生物製劑公司在2025年7月發布的「2025年第二季財務業績報告」顯示，該公司在上半年獲得了價值24億美元的生產契約，凸顯了其龐大的生產規模，而這依賴於完善的檢測策略。

市場挑戰

與評估替代快速檢測技術相關的監管複雜性嚴重阻礙了全球黴漿菌檢測市場的成長。儘管製造商尋求引入自動化快速檢測技術以取代傳統的28天培養方法，從而加快保存期限短的治療藥物的上市，但監管機構卻提出了嚴格的可比性要求。企業必須證明這些快速檢測方法的檢測極限與既定的藥典通訊協定無法區分。這項規定需要耗費大量成本和時間檢驗研究，這往往會延緩快速檢測系統的應用，並抑制高價值快速檢測耗材的持續銷售。

這些營運障礙阻礙了市場充分利用生物製藥產業的擴張。根據再生醫學聯盟的數據，預計到2025年，全球治療藥物研發公司的數量將增加6%。雖然這表明測試解決方案的基本客群正在擴大，但繁瑣的檢驗程序卻阻礙了研發人員轉向更先進的調查方法。因此，製造商被迫依賴過時且緩慢的測試流程，而不是採用能夠提升市場價值的優質快速解決方案，從而延緩了市場收入的累積。

市場趨勢

從基於培養的方法向核酸擴增技術 (NAT) 的轉變正在加速。這主要是由於生物製藥產業迫切需要快速批次放行。傳統的 28 天培養檢測對於保存期限有限的治療藥物而言已成為瓶頸，因此製造商正在轉向分子生物學方法，這些方法在提供相當靈敏度的同時，顯著縮短了周轉時間。現代檢測方法的性能充分體現了這種操作方式的轉變。如同 Eurofins 2025 年 6 月發布的《生物製藥服務新聞 - 2025 年夏季刊》中所述，檢驗的NAT 平台（例如 MycoSEQ）可在不到五天內提供黴漿菌檢測的確認結果。檢測時間的顯著縮短使生物製藥開發商能夠在遵守嚴格安全法規的同時，加快產品放行計畫。

同時，隨著越來越多的公司尋求為複雜的商業化階段試驗提供專門的基礎設施，對受託研究機構(CRO) 的日益依賴正在重塑市場格局。生物製藥開發商正透過利用提供一體化生產和品管服務的外部合作夥伴來簡化其供應鏈，從而避免擴大自有實驗室所需的大量資本投資。這種策略整合趨勢在近期的產業發展中顯而易見。 2025年5月，Minaris Advanced Therapies在ISCT年會上發布新聞稿，宣布“新公司成立”，並表示該公司已將Minaris Regenerative Medicines與無錫先進療法株式會社的美國和英國分部合併。此次合併創建了一個全球性組織，為超過27種商業產品提供測試服務，顯示市場對大型綜合測試服務提供者的依賴程度日益加深。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球黴漿菌檢測市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品分類（儀器、試劑盒、試劑）
  • 透過技術（PCR、ELISA、酵素法、DNA染色等）
  • 按應用領域（細胞株測試、生物生產測試等）
  • 按最終用戶（學術研究機構、細胞庫、合約研究組織、製藥/生物技術公司等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美黴漿菌檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲黴漿菌檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區黴漿菌檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲黴漿菌檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美黴漿菌檢測市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球黴漿菌檢測市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Mycoplasma Testing Market is projected to expand from USD 1097.92 Million in 2025 to USD 2348.42 Million by 2031, reflecting a compound annual growth rate (CAGR) of 13.51%. Mycoplasma testing involves analytical protocols designed to identify Mollicutes contamination within cell banks, raw materials, and finished biopharmaceutical goods to guarantee patient safety. This market is chiefly bolstered by the rising quantity of biopharmaceutical production and strict regulatory requirements mandating that products remain free of adventitious agents before release. Additionally, the commercial introduction of advanced therapeutic medicinal products, which necessitate stringent quality assurance, serves as a key growth engine. As reported by the Alliance for Regenerative Medicine in 2025, 35% of global revenue derived from cell and gene therapies originated outside the United States, highlighting the broadening international scope of the biologics industry that demands extensive testing frameworks.

Despite strong market demand, growth is hindered by the regulatory difficulties involved in validating rapid alternative methods intended to supersede traditional 28-day culture assays. Manufacturers frequently encounter significant obstacles in proving that faster, automated technologies offer detection limits equivalent to established compendial standards. These validation challenges often postpone the integration of efficient testing solutions for therapies with short shelf lives.

Market Driver

The escalating global requirement for biologics and biosimilars serves as a primary propellant for the mycoplasma testing market, fundamentally altering quality control standards. As pharmaceutical developers hasten the commercial launch of complex molecules, the necessity for mandatory lot release testing for adventitious agents increases proportionally to safeguard patient health. This pattern is confirmed by persistent regulatory momentum; for instance, Fierce Pharma reported in January 2026 that the U.S. FDA's Center for Drug Evaluation and Research authorized 46 novel drugs in 2025. This continuous arrival of new therapies necessitates rigorous sterility verification and expanded testing protocols to minimize contamination risks throughout the product's life cycle.

Concurrently, the substantial enlargement of biopharmaceutical manufacturing capabilities drives market growth, as corporations upgrade infrastructure to satisfy global supply demands. New production sites mandate comprehensive validation, encompassing utility monitoring and raw material analysis, which markedly boosts the usage of mycoplasma detection assays. To demonstrate this investment trend, Amgen announced in a September 2025 press release that it had dedicated $650 million to extending its U.S. manufacturing network, thereby establishing new operational hubs that require biosafety oversight. Moreover, the outsourcing industry reflects this expansion; according to Samsung Biologics' 'Second Quarter 2025 Financial Results' released in July 2025, the firm obtained sales contracts amounting to $2.4 billion in the first half of the year, emphasizing the massive scale of manufacturing operations dependent on robust testing strategies.

Market Challenge

The regulatory intricacies tied to validating rapid alternative techniques notably obstruct the growth of the Global Mycoplasma Testing Market. While manufacturers aim to supersede traditional 28-day culture assays with accelerated automated technologies to speed up the release of short-shelf-life treatments, regulatory bodies impose rigorous comparability requirements. Companies must demonstrate that these rapid methods attain detection limits indistinguishable from established compendial protocols. This stipulation leads to costly and prolonged validation studies, which often postpone the deployment of faster testing systems and curtail recurring sales of high-value rapid testing consumables.

This operational impediment hinders the market from fully leveraging the broader expansion of the biopharmaceutical industry. Data from the Alliance for Regenerative Medicine indicates that the global count of therapeutic developers rose by 6% in 2025. While this suggests a growing client base for testing solutions, the onerous validation procedure deters these developers from transitioning to advanced methodologies. As a result, the market undergoes retarded revenue accumulation because manufacturers are compelled to depend on slower, legacy testing processes instead of embracing premium rapid solutions that would enhance market value.

Market Trends

The shift from culture-based techniques to Nucleic Acid Amplification Techniques (NAT) is gaining momentum, fueled by the urgent necessity for rapid lot release in biomanufacturing. Since traditional 28-day culture assays generate bottlenecks for therapeutics with limited shelf lives, manufacturers are turning to molecular alternatives that provide equivalent sensitivity with drastically shortened turnaround times. This operational transition is highlighted by the performance of contemporary assays; as noted in Eurofins' 'BioPharma Services News - Summer 2025' report from June 2025, validated NAT platforms like MycoSEQ are capable of delivering confirmed mycoplasma detection results in fewer than five days. This significant decrease in testing time enables biopharmaceutical developers to accelerate product release schedules while adhering to rigorous safety regulations.

At the same time, the rising reliance on outsourcing to Contract Research Organizations (CROs) is restructuring the market environment, as companies pursue specialized infrastructure for intricate commercial-stage testing. Biopharmaceutical developers are streamlining their supply chains by engaging external partners who provide unified manufacturing and quality control services, thereby circumventing the steep capital expenditures associated with internal lab expansion. This movement toward strategic consolidation is exemplified by recent industry developments; according to a May 2025 press release by Minaris Advanced Therapies regarding the 'New company unveiled at the annual ISCT conference,' the firm merged Minaris Regenerative Medicine with the U.S. and U.K. divisions of WuXi Advanced Therapies. This union created a global entity managing testing services for more than 27 commercial products, underscoring the sector's increasing dependence on large-scale, integrated testing providers.

Key Market Players

• Agilent Technologies Inc
• ATCC
• Bionique Testing Laboratories Inc.
• Charles River Laboratories International Inc.
• Lonza Group Ltd
• Merck KGaA
• Bionique Testing Laboratories Inc.
• PromoCell GmbH
• Thermo Fisher Scientific Inc.
• Sartorius AG

Report Scope

In this report, the Global Mycoplasma Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Mycoplasma Testing Market, By Product

• Instruments
• Kits and Reagents

Mycoplasma Testing Market, By Technology

• PCR
• ELISA
• Enzymatic Methods
• DNA Staining
• Other

Mycoplasma Testing Market, By Application

• Cell Line Testing
• Bioproduction Testing
• Other

Mycoplasma Testing Market, By End-User

• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

Mycoplasma Testing Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Mycoplasma Testing Market.

Available Customizations:

Global Mycoplasma Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Mycoplasma Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Instruments, Kits and Reagents)
  • 5.2.2. By Technology (PCR, ELISA, Enzymatic Methods, DNA Staining, Other)
  • 5.2.3. By Application (Cell Line Testing, Bioproduction Testing, Other)
  • 5.2.4. By End-User (Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Mycoplasma Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Technology
  • 6.2.3. By Application
  • 6.2.4. By End-User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Mycoplasma Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Technology
      • 6.3.1.2.3. By Application
      • 6.3.1.2.4. By End-User
  • 6.3.2. Canada Mycoplasma Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Technology
      • 6.3.2.2.3. By Application
      • 6.3.2.2.4. By End-User
  • 6.3.3. Mexico Mycoplasma Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Technology
      • 6.3.3.2.3. By Application
      • 6.3.3.2.4. By End-User

7. Europe Mycoplasma Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Technology
  • 7.2.3. By Application
  • 7.2.4. By End-User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Mycoplasma Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Technology
      • 7.3.1.2.3. By Application
      • 7.3.1.2.4. By End-User
  • 7.3.2. France Mycoplasma Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Technology
      • 7.3.2.2.3. By Application
      • 7.3.2.2.4. By End-User
  • 7.3.3. United Kingdom Mycoplasma Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Technology
      • 7.3.3.2.3. By Application
      • 7.3.3.2.4. By End-User
  • 7.3.4. Italy Mycoplasma Testing Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Technology
      • 7.3.4.2.3. By Application
      • 7.3.4.2.4. By End-User
  • 7.3.5. Spain Mycoplasma Testing Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Technology
      • 7.3.5.2.3. By Application
      • 7.3.5.2.4. By End-User

8. Asia Pacific Mycoplasma Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Technology
  • 8.2.3. By Application
  • 8.2.4. By End-User
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Mycoplasma Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Technology
      • 8.3.1.2.3. By Application
      • 8.3.1.2.4. By End-User
  • 8.3.2. India Mycoplasma Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Technology
      • 8.3.2.2.3. By Application
      • 8.3.2.2.4. By End-User
  • 8.3.3. Japan Mycoplasma Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Technology
      • 8.3.3.2.3. By Application
      • 8.3.3.2.4. By End-User
  • 8.3.4. South Korea Mycoplasma Testing Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Technology
      • 8.3.4.2.3. By Application
      • 8.3.4.2.4. By End-User
  • 8.3.5. Australia Mycoplasma Testing Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Technology
      • 8.3.5.2.3. By Application
      • 8.3.5.2.4. By End-User

9. Middle East & Africa Mycoplasma Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Technology
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Mycoplasma Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Technology
      • 9.3.1.2.3. By Application
      • 9.3.1.2.4. By End-User
  • 9.3.2. UAE Mycoplasma Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Technology
      • 9.3.2.2.3. By Application
      • 9.3.2.2.4. By End-User
  • 9.3.3. South Africa Mycoplasma Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Technology
      • 9.3.3.2.3. By Application
      • 9.3.3.2.4. By End-User

10. South America Mycoplasma Testing Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Technology
  • 10.2.3. By Application
  • 10.2.4. By End-User
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Mycoplasma Testing Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Technology
      • 10.3.1.2.3. By Application
      • 10.3.1.2.4. By End-User
  • 10.3.2. Colombia Mycoplasma Testing Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Technology
      • 10.3.2.2.3. By Application
      • 10.3.2.2.4. By End-User
  • 10.3.3. Argentina Mycoplasma Testing Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Technology
      • 10.3.3.2.3. By Application
      • 10.3.3.2.4. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Mycoplasma Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Agilent Technologies Inc
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. ATCC
• 15.3. Bionique Testing Laboratories Inc.
• 15.4. Charles River Laboratories International Inc.
• 15.5. Lonza Group Ltd
• 15.6. Merck KGaA
• 15.7. Bionique Testing Laboratories Inc.
• 15.8. PromoCell GmbH
• 15.9. Thermo Fisher Scientific Inc.
• 15.10. Sartorius AG

16. Strategic Recommendations

17. About Us & Disclaimer